Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Revival of anti-angiogenic therapies in cancer—news on an old therapeutic concept

Revival of anti-angiogenic therapies in cancer—news on an old therapeutic concept editorial memo (2017) 10:185–186 https://doi.org/10.1007/s12254-017-0363-z Revival of anti-angiogenic therapies in cancer—news on an old therapeutic concept Andreas Pircher Received: 31 October 2017 / Accepted: 31 October 2017 / Published online: 16 November 2017 © Springer-Verlag GmbH Austria, part of Springer Nature 2017 Inhibition of angiogenesis became clinical reality in and metastatic renal cell cancer (mRCC) by Pichler 2004 with the approval of bevacizumab in metastatic et al. [2]. In both cancer entities anti-angiogenic drugs colorectal cancer and we are now approaching the are successfully used; however, there is still a high expiration dates of the patents for bevacizumab in medical need for biomarker identification and opti- the US in July 2019 and in Europe in January 2022. mal patient selection. Also in other urological malig- From the historical view on anti-angiogenic drug de- nancies besides mRCC anti-angiogenic therapies pose velopment, mainly targeting the vascular endothelial an attractive therapeutic strategy and Haidl et al. [3] growth factor (VEGF) pathway, there were several ups summarize the first evidence to use to use anti-an- and downs with the use of these agents, and the first giogenic drugs in prostate, bladder, testicular as well euphoric view on the concept to starve tumors by http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Revival of anti-angiogenic therapies in cancer—news on an old therapeutic concept

Download PDF
2 pages

Loading next page...
 
/lp/springer-journals/revival-of-anti-angiogenic-therapies-in-cancer-news-on-an-old-pL8SGmMd1w
Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer-Verlag GmbH Austria, part of Springer Nature
Subject
Medicine & Public Health; Oncology; Medicine/Public Health, general
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-017-0363-z
Publisher site
See Article on Publisher Site

Abstract

editorial memo (2017) 10:185–186 https://doi.org/10.1007/s12254-017-0363-z Revival of anti-angiogenic therapies in cancer—news on an old therapeutic concept Andreas Pircher Received: 31 October 2017 / Accepted: 31 October 2017 / Published online: 16 November 2017 © Springer-Verlag GmbH Austria, part of Springer Nature 2017 Inhibition of angiogenesis became clinical reality in and metastatic renal cell cancer (mRCC) by Pichler 2004 with the approval of bevacizumab in metastatic et al. [2]. In both cancer entities anti-angiogenic drugs colorectal cancer and we are now approaching the are successfully used; however, there is still a high expiration dates of the patents for bevacizumab in medical need for biomarker identification and opti- the US in July 2019 and in Europe in January 2022. mal patient selection. Also in other urological malig- From the historical view on anti-angiogenic drug de- nancies besides mRCC anti-angiogenic therapies pose velopment, mainly targeting the vascular endothelial an attractive therapeutic strategy and Haidl et al. [3] growth factor (VEGF) pathway, there were several ups summarize the first evidence to use to use anti-an- and downs with the use of these agents, and the first giogenic drugs in prostate, bladder, testicular as well euphoric view on the concept to starve tumors by

Journal

memo - Magazine of European Medical Oncology – Springer Journals

Published: Nov 16, 2017

References

  • Antiangiogenic therapies in colorectal cancer
    Stragier, E; Prenen, H
  • Novel concepts of antiangiogenic therapies in metastatic renal cell cancer
    Pichler, R; Heidegger, I
  • Antiangiogenic therapies in urogenital malignancies—fiction or fact?
    Haidl, F; Pfister, D; Heidenreich, A; Heidegger, I
  • Antiangiogenic therapies in breast cancer
    Gampenrieder, S; Westphal, T; Greil, R
  • Antiangiogenic therapies for the treatment of angiosarcoma: a clinical update
    Young, R; Woll, P